Advertisement
FATE vs FDMT
Which Stock Would AI Choose? Fate Therapeutics (FATE) vs. 4D Molecular Therapeutics (FDMT) Stock Comparison
Key Takeaways
- FATE is a clinical-stage developer of off-the-shelf, induced pluripotent stem cell (iPSC)-derived cell therapies, while FDMT is a clinical-stage gene therapy company focused on ophthalmology.
- FATE has delivered sharper price momentum over recent months, while FDMT carries a more advanced, late-stage pipeline with clearer catalysts.
- FDMT holds a larger cash balance and longer runway, while FATE remains more exposed to funding and cash-burn considerations.
- Both names are pre-profitability biotechs, making clinical data readouts and regulatory milestones the primary drivers of relative performance and market positioning.
- Get more context on these tickers by exploring FATE Major News and FATE Today's Price Move, plus FDMT Major News and FDMT Today's Price Move.
- To see how automated systems are currently navigating these and other stocks, explore Trending AI Robots.
Introduction
Investors screening the biotech sector often face a choice between emerging platforms with high upside and more mature pipelines with nearer-term catalysts. FATE (Fate Therapeutics) and FDMT (4D Molecular Therapeutics) illustrate this trade-off well. Both are clinical-stage, pre-revenue-to-minimal-revenue companies trading at single- to mid-teens price levels, yet they operate in different therapeutic areas and sit at different stages of development. This stock comparison examines their relative performance, business models, risk profiles, and market positioning to help traders and investors assess which profile better suits their objectives.
FATE Overview and Recent Performance
FATE (Fate Therapeutics) develops "off-the-shelf" cellular immunotherapies built from a clonal master iPSC (induced pluripotent stem cell) bank. Its pipeline centers on CAR (chimeric antigen receptor) T-cell and NK (natural killer) cell candidates such as FT819, which is being evaluated in autoimmune conditions including lupus nephritis and systemic lupus erythematosus (SLE), as well as in oncology.
In recent market activity, FATE has been one of the stronger performers in the small-cap biotech space, rising sharply over the course of the year. The advance has been supported by preliminary clinical data pointing to patient responses in autoimmune settings and a favorable safety profile, alongside reiterated analyst ratings. At the same time, the company continues to report modest collaboration revenue in the low single-digit millions against a quarterly net loss in the tens of millions, and its cash runway—reported in the mid-$170 million range—extends into 2028. This combination of positive data momentum and persistent cash burn has kept sentiment divided between optimism about the platform and concern about financing risk.
FDMT Overview and Recent Performance
FDMT (4D Molecular Therapeutics) develops targeted and evolved AAV (adeno-associated virus) vector-based gene therapies, with a primary focus on ophthalmology. Its lead candidate, 4D-150, is a single-dose therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), designed to reduce the burden of frequent anti-VEGF injections.
Over recent weeks, FDMT has also posted notable gains, though its year-to-date advance has been more moderate than that of FATE. The company's Phase 3 4FRONT program for wet AMD is advancing, with enrollment completion expected in the second half of 2026 and topline data anticipated in 2027. A strategic partnership provides milestone and cost-sharing support, and the company's cash position—reported in the range of roughly $450 million to $550 million—supports operations into 2028. Sentiment reflects a balance between the promise of a disruptive, less-frequent dosing paradigm and the uncertainty inherent in pivotal gene therapy readouts.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each running distinct strategies, timeframes, and risk parameters. Because market conditions shift constantly, only a subset of these bots remains well-suited to the current environment at any given time. Tickeron curates the strongest performers into a dedicated Trending AI Robots section, where users can review available bots by style, timeframe, historical performance, and the specific tickers they trade. This offers a data-driven way to observe how automated systems are positioning across names like FATE and FDMT. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The clearest contrast between these two companies is developmental stage and therapeutic focus. FDMT operates in ophthalmology with a lead program already in Phase 3, giving it more defined, near-to-medium-term regulatory catalysts. FATE operates in cell therapy across oncology and autoimmune disease, with lead programs largely in earlier-stage trials—higher upside potential but greater clinical uncertainty.
Financially, FDMT holds a meaningfully larger cash balance and a longer operational runway, which reduces near-term dilution risk relative to FATE. However, FATE has generated stronger recent price momentum, suggesting the market is assigning a premium to its platform narrative and autoimmune data. In terms of market positioning, FDMT competes in a crowded gene therapy and anti-VEGF landscape, while FATE competes in an emerging off-the-shelf cell therapy field with fewer direct "allogeneic" comparators. Both remain sensitive to binary clinical outcomes and sector-wide biotech sentiment.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward FDMT on a stability-adjusted basis. The combination of a late-stage Phase 3 asset, a larger cash buffer, established strategic backing, and clearly defined catalysts in 2026–2027 supports a comparatively more consistent risk-reward profile. FATE, by contrast, exhibits stronger short-term trend momentum but carries earlier-stage clinical uncertainty and a heavier cash-burn profile. The AI's preference is therefore probabilistic rather than absolute: investors prioritizing momentum may favor FATE, while those prioritizing pipeline maturity and balance-sheet stability may find FDMT the more compelling of the two.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and FDMT is a Buy.
FATE in +3.98% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 85 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FATE entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.498). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FDMT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for FDMT turned positive on October 29, 2026. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in 41 of 47 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FDMT's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 57 cases where FDMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 217 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FDMT as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FDMT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.660) is normal, around the industry mean (3.498). P/E Ratio (-4.658) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FATE | FDMT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 64 | 42 | |
P/E GROWTH RATING 1..100 | 13 | 58 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FDMT's Valuation (24) in the null industry is in the same range as FATE (51) in the Biotechnology industry. This means that FDMT’s stock grew similarly to FATE’s over the last 12 months.
FDMT's Profit vs Risk Rating (100) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that FDMT’s stock grew similarly to FATE’s over the last 12 months.
FDMT's SMR Rating (97) in the null industry is in the same range as FATE (98) in the Biotechnology industry. This means that FDMT’s stock grew similarly to FATE’s over the last 12 months.
FDMT's Price Growth Rating (42) in the null industry is in the same range as FATE (64) in the Biotechnology industry. This means that FDMT’s stock grew similarly to FATE’s over the last 12 months.
FATE's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for FDMT (58) in the null industry. This means that FATE’s stock grew somewhat faster than FDMT’s over the last 12 months.
| FATE | FDMT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| Advances ODDS (%) | 10 days ago 87% | 5 days ago 83% |
| Declines ODDS (%) | 1 day ago 90% | 12 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 75% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FATE’s FA Score shows that 1 FA rating(s) are green while FDMT’s FA Score has 1 green FA rating(s).
- FATE’s FA Score: 1 green, 4 red.
- FDMT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FATE’s TA Score shows that 4 TA indicator(s) are bullish while FDMT’s TA Score has 5 bullish TA indicator(s).
- FATE’s TA Score: 4 bullish, 4 bearish.
- FDMT’s TA Score: 5 bullish, 4 bearish.
Price Growth
FATE (@Biotechnology) experienced а -27.57% price change this week, while FDMT (@Biotechnology) price change was +7.69% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.04%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -16.99%.
Reported Earning Dates
FATE is expected to report earnings on Mar 01, 2027.
FDMT is expected to report earnings on Feb 26, 2027.
Industries' Descriptions
@Biotechnology (+2.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FDMT and
Correlation & Price change
A.I.dvisor indicates that over the last year, FDMT has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FDMT jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To FDMT | 1D Price Change % | ||
|---|---|---|---|---|
| FDMT | 100% | -6.74% | ||
| KYTX - FDMT | 59% Loosely correlated | -1.76% | ||
| PRME - FDMT | 55% Loosely correlated | -9.53% | ||
| RCKT - FDMT | 55% Loosely correlated | -3.63% | ||
| EDIT - FDMT | 54% Loosely correlated | -10.08% | ||
| SLDB - FDMT | 54% Loosely correlated | -7.89% | ||
More | ||||